Pharmacogenomics Market
Global Pharmacogenomics Market reached at a CAGR during the forecast period 2024-2031.
Pharmacogenomics is the study of how an individual’s genetic makeup influences their response to drugs. By understanding these genetic factors, pharmacogenomics aims to optimize drug therapies, ensuring patients receive the most effective medications with fewer side effects. This field is revolutionizing personalized medicine, offering tailored treatments based on genetic profiles, and improving overall healthcare outcomes.
As the field continues to grow, pharmacogenomics holds the potential to transform how we approach drug prescriptions, making them more precise and individualized.
Download Free Sample PDF: https://www.datamintelligence.com/download-sample/pharmacogenomics-market
Market Growth Drivers:
Rising Demand for precision medicine
The increasing demand for precision medicine is set to fuel market growth in the coming years. A key factor driving this shift is the advancement of pharmacogenomics, which is revolutionizing healthcare by enabling personalized treatments based on an individual’s unique DNA. This approach has the potential to improve health outcomes, enhance patient well-being, and reduce healthcare costs by preventing hospitalizations and minimizing ineffective treatments caused by adverse drug reactions.
The main goal is to make pharmacogenomic-guided prescribing widely adopted, which would help reduce NHS costs while enhancing patient outcomes. By empowering healthcare professionals to offer more personalized and efficient care, this approach ensures treatments are tailored to each individual.
The focus on personalized care highlights the importance of understanding how genetic factors influence drug responses. This technology is vital for identifying genetic variants that impact drug effectiveness and metabolism. For example, in May 2022, Invitae launched its 38-gene Invitae Pharmacogenomics Panel, which includes both a Mental Health Panel and a clinical decision support tool to help healthcare providers make more informed treatment choices.
Market Segments:
By Type: Genotyping Kits, Sequencing Instruments, PCR Reagents and Consumables, Sample Preparation Kits, Others, Services Genetic Testing Services, Pharmacogenomic Consulting, Others, Software Bioinformatics Software, Clinical Decision Support System, Laboratory Information Management System, EHR Integration Software, Others
By Technology: DNA Sequencing , Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Other Technologies
By Application: Drug Discovery, Neurology, Oncology, Pain Management, Other Applications
By End User: Hospital , Specialty Clinics, Academic and Research Institutes, Pharmaceuticals
By Region: North America, Latin America, Europe, Asia Pacific, Middle East and Africa
Top Key Players in Pharmacogenomics:
- Abbott
- Agilent Technologies Inc.
- Becton, Dickinson and Company
- bioMerieux SA
- Bio-Rad Laboratories Inc
- Illumine, Inc.
- Eurofins Scientific
- PacBio
- QIAGEN
- Thermo Fisher Scientific Inc
Customize Your Scope: https://www.datamintelligence.com/customize/pharmacogenomics-market
Regional Growth
North America holds a significant share of the market, accounting for about 41.4%
The North America region is anticipated to maintain the largest market share throughout the forecast period. The growing demand for pharmacogenomics is mainly driven by the increasing prevalence of chronic conditions like cancer, cardiovascular diseases, and neurological disorders. This genetic testing technology plays a crucial role in helping oncologists identify genetic variations and predict how patients will respond to cancer treatments, enabling the selection of the most effective targeted therapies.
The introduction of new products and services by key market players is expected to drive growth in this sector. For example, in May 2022, Blue Care Network launched Blue Cross Personalized Medicine in Michigan, an end-to-end pharmacogenomics precision medicine initiative. This project reviews a list of recommended drugs for various behavioral, oncological, and cardiovascular health conditions and uses genetic testing to tailor prescription therapies to individual patients. Additionally, the University of Chicago’s 1200 Patients Project focused on exploring the feasibility and benefits of proactive pharmacogenomic testing for a set of specific genes.
Key Development
On July 25, 2023, Illumina Inc. joined forces with Pillar Biosciences Inc. to expand its portfolio by incorporating Pillar’s oncology assays. This collaboration aims to offer a broader range of sequencing options, making cancer testing more efficient, accurate, and cost-effective, ultimately improving access to personalized cancer treatments.
On May 9, 2023, Pfizer and Thermo Fisher Scientific formed a partnership to enhance the availability of personalized, next-generation sequencing-based testing for cancer patients in global markets. The collaboration focuses on over 30 countries where access to affordable genetic testing is limited or unavailable, aiming to increase access to advanced testing for breast and lung cancer.
